Similar Items: Worth their weight in gray matter? A narrative review of cost‐effectiveness analyses of monoclonal antibodies for Alzheimer's disease
- White matter hyperintensities in Alzheimer's disease in the era of anti‐amyloid therapies
- Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment
- Alzheimer's disease drug development pipeline: 2026
- Interchangeability of CSF and PET to identify Alzheimer's disease pathology
- Atrophy signature for alpha‐synuclein copathology in Alzheimer's disease
- CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design